Flunitrazolam (FNTZ, Flunazolam) is a
triazolobenzodiazepine (TBZD), which are
benzodiazepine (BZD) derivatives, that has been sold online as a
designer drug, and is a potent
hypnotic and
sedative drug similar to related compounds such as
flunitrazepam,
clonazolam and
flubromazolam. It was first definitively identified and reported to the
EMCDDA Early Warning System, by an analytical laboratory in Germany in October 2016,[1] and had not been described in the scientific or patent literature before this.[2] It is the triazole analogue of
Flunitrazepam (Rohypnol). The addition of the
triazole ring to the scaffold increases potency significantly, this is evident as flunitrazolam is reported anecdotally to be active in the
microgram level. It is active at 0.1 mg.[3][4]
^Ameline A, Richeval C, Gaulier JM, Raul JS, Kintz P (February 2019). "Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism". Drug Testing and Analysis. 11 (2): 223–229.
doi:
10.1002/dta.2480.
PMID30109775.
S2CID52001932.